Investors

Webcast ImageWebcast
Q1 2016 Xtant Medical Holdings Inc Earnings Conference Call (Live)
05/05/16 at 9:00 a.m. ET
Q1 2016 Xtant Medical Holdings Inc Earnings Conference Call
Thursday, May 5, 2016 9:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and...
More

Stock Quote
XTNT (Common Stock)
Price$2.20
Change (%) - 0.19 (7.95%)
Volume7,208
Data as of 04/29/16 4:02 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: XTNT.K.  Currently trading at $2.20 with a 52 week high of $4.49 and a 52 week low of $2.02.
Recent News
DateTitle 
04/27/16Xtant Medical Holdings, Inc. to Report First Quarter 2016 Financial Results on May 4, 2016
BELGRADE, Mont., April 27, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the period ended March 31st, 2016, at the close of the financial markets on May 4, 2016. An accompanying conference call will be hosted by Dan Goldberger, Chief Executive Officer, and John Gandolfo, Chief Financial Officer, to discuss the results. The c... 
04/26/16Xtant Medical Announces Montana Department of Commerce Grant Awards
BELGRADE, Mont., April 26, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the awarding of two grants from the Montana Department of Commerce totaling $155,000 to aid Bacterin International, Inc., or Bacterin, in the expansion of its orthobiologic processing facility. Bacterin is a wholly owned subsidiary of Xtant Medical Holdings, Inc. The Big Sky Economic Development T... 
04/19/16Xtant Medical Pre-Announces First Quarter 2016 Revenue
Core recurring revenue to increase 7% to 8% over first quarter 2015 The Company reiterates full-year 2016 revenue guidance of $94 million to $99 million and EBITDA guidance of $4.3 million to $6.3 million BELGRADE, Mont., April 19, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, pre-announced that its first quarter 2016 revenue is expected to be in the range of $20.9 million t... 
03/30/16Xtant Medical Announces FDA Clearance of the Xspan™ Laminoplasty Fixation System
BELGRADE, Mont., March 30, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiary, X-spine Systems, received FDA clearance of the Xspan™ Laminoplasty Fixation System. About the Xspan™ Laminoplasty Fixation System The Xspan™ System represents the latest generation of laminoplasty fixation. Spinal laminoplasty is a surgical procedure performed to r... 
More

Upcoming Events
DateTitle
05/05/16 9:00 a.m. ET
Q1 2016 Xtant Medical Holdings Inc Earnings Conference Call
05/25/16
Xtant Medical Holdings Inc at the B. Riley & Co’s 17th Annual Investor Conference
06/01/16
Xtant Medical Holdings Inc at the Marcum Microcap Conference
More

Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Xtant Medical Holdings Inc posts new information to the site. Just enter your e-mail address and click Submit.